New York, NY – October 9, 2025 – Pfizer Inc. (NYSE:PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of 2025. This latest payout marks a significant milestone: the company's 348th consecutive quarterly dividend. The unwavering consistency of
Eli Lilly and Company (NYSE: LLY) has announced the completion of its Phase 1 bioavailability study for the combination of Bimagrumab and Tirzepatide on October 8, 2025, a foundational step in understanding the pharmacokinetic profile of this potential therapy. While this marks a technical advancement in drug development, the news
Amazon (NASDAQ: AMZN) continues to aggressively expand its strategic business developments, solidifying its e-commerce dominance through frequent Prime discount events and making significant inroads into the pharmacy sector. These initiatives, spanning from late 2023 through 2025, are designed to strengthen customer loyalty, capture new markets, and leverage Amazon's robust logistics
Investors reacted to the company’s leadership shake-up and new data from its ulcerative colitis therapy Omvoh showing sustained remission over four years.
On a day where the broader S&P 500 and Nasdaq Composite indices soared to new all-time record highs, the S&P 500 Healthcare sector presented a compelling, albeit nuanced, narrative of market leadership and resilience. While the overall market sentiment exuded robust optimism, the healthcare sector itself showcased a
Shares of healthcare diagnostics company QuidelOrtho (NASDAQ:QDEL)
fell 4.4% in the morning session after Citigroup analyst Patrick Donnelly downgraded the stock to 'Neutral' from 'Buy' and lowered the price target. The firm cut its price projection for QuidelOrtho to $33 from $40, a reduction of 17.5%. This adjustment by Citigroup reflected a change in the firm's outlook on the company's stock performance. The downgrade and price target cut highlighted concerns about QuidelOrtho's near-term growth prospects.
Eli Lilly just got great news, courtesy of Pfizer and Trump, leading shares to their highest level in five months. Its rally may just be getting started.
In a monumental stride towards democratizing global healthcare, researchers at the University of Liverpool have announced the development of a pioneering low-cost, handheld, AI-powered blood test designed for the early detection of Alzheimer's disease biomarkers. This groundbreaking innovation, widely reported between October 1st and 6th, 2025, promises to revolutionize how Alzheimer's is diagnosed, making testing [...]
